The study reveals that of the 25 investors who provided voting data on the executive pay policy of drugs giant GlaxoSmithKline, three voted for, four abstained and 18 voted against. Corporate history was made last year when 51% of shareholders voted against the remuneration policy in protest at the £22m pay-off the company's chief executive, Jean-Pierre Garnier, would receive if fired.